5,4'-dihydroxy-7-(1-carboxymethoxy)flavone

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 5,4'-dihydroxy-7-(1-carboxymethoxy)flavone
• 英文别名: 2-[5-Hydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxyacetic acid；2-[5-hydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxyacetic acid
• 化学式: C₁₇H₁₂O₇
• 分子量: 328.278
• InChiKey: CMGRYZUEGLDACO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5,4'-dihydroxy-7-(1-carboxymethoxy)flavone 、 炔丙胺 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.08h， 以70%的产率得到2-[5-hydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxy-N-prop-2-ynylacetamide
  参考文献：
  名称：

  [EN] MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM
  [FR] GEL INJECTABLE THERMOSENSIBLE À BASE DE PRO-MÉDICAMENT MACROMOLÉCULAIRE EN TANT QUE NOUVELLE PLATEFORME D'ADMINISTRATION DE MÉDICAMENT

  摘要：

  这种应用披露了基于前药的热敏凝胶（“ProGel”），由dmg分子与水溶性聚合物载体的共轭物组成，能够将dmg分子控制释放到受试者的组织中。还披露了将ProGel-药物共轭物用于治疗各种疾病或紊乱的方法以及制备它们的方法。

  公开号：

  WO2020087057A1
• 作为产物：
  描述：

  德国春黄菊油 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 0.5h， 生成 5,4'-dihydroxy-7-(1-carboxymethoxy)flavone
  参考文献：
  名称：

  C-7 modified flavonoids as novel tyrosyl-tRNA synthetase inhibitors

  摘要：

  二十种经过改良的C-7类黄酮类化合物被设计并合成。

  DOI：

  10.1039/c6ra28061g

文献信息

• 新的α-葡萄糖苷酶抑制剂
  申请人：中国人民解放军军事医学科学院毒物药物研究所

  公开号：CN106187970A

  公开（公告）日：2016-12-07

  本发明提供式I所示的具有选择性α-葡萄糖苷酶抑制作用的新的芹菜素类衍生物，或其药学上可接受的盐类：其中，R1和R2各自独立地为H或-(CH2)nCOOR3；R3为H，或C1-C5的直链或支链烷基；n为1-10的整数；R1和R2相同或不同，但是R1和R2不能同时为H。
• Discovery of xanthine oxidase inhibitors and/or α-glucosidase inhibitors by carboxyalkyl derivatization based on the flavonoid of apigenin
  作者：Zhuo-Ran Su、Shi-Yong Fan、Wei-Guo Shi、Bo-Hua Zhong

  DOI：10.1016/j.bmcl.2015.05.016

  日期：2015.7

  Three series of apigenin derivatives have been prepared by coupling the carboxyl alkyl group to 4'-, 5- or 7-hydroxyl groups of apigenin respectively. Preliminary biological evaluation in vitro revealed that xanthine oxidase inhibitory activity was improved by modifications at 4'-position and decreased by similar modifications at 5-, 7-positions while alpha-glucosidase inhibitory activity was maintained by modifications at 5-, 7-positions but lost by modifications at 4'-position. Administration (ip) of 7e markedly lowered serum uric acid levels in potassium oxonate induced hyperuricemic mouse model and administration (p.o.) of 11d or 11e effectively suppressed the elevation of serum glucose in the oral sucrose tolerance test in mice, while apigenin were not significantly effective in both tests. (C) 2015 Elsevier Ltd. All rights reserved.
• MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM
  申请人：Board of Regents of the University of Nebraska

  公开号：US20220008543A1

  公开（公告）日：2022-01-13

  This application discloses prodrug-based thermosensitive gel (“ProGel”) comprised of conjugates of dmg molecules with water-soluble polymeric carriers, which are capable of controlled release of the dmg molecules into the tissue of a subject. Use of the ProGel-Drug conjugates for treatment of various diseases or disorders and methods of preparing them are also disclosed.
• [EN] MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM<br/>[FR] GEL INJECTABLE THERMOSENSIBLE À BASE DE PRO-MÉDICAMENT MACROMOLÉCULAIRE EN TANT QUE NOUVELLE PLATEFORME D'ADMINISTRATION DE MÉDICAMENT
  申请人：UNIV NEBRASKA

  公开号：WO2020087057A1

  公开（公告）日：2020-04-30

  This application discloses prodrug-based thermosensitive gel ("ProGel") comprised of conjugates of dmg molecules with water-soluble polymeric carriers, which are capable of controlled release of the dmg molecules into the tissue of a subject. Use of the ProGel-Drug conjugates for treatment of various diseases or disorders and methods of preparing them are also disclosed.

  这种应用披露了基于前药的热敏凝胶（“ProGel”），由dmg分子与水溶性聚合物载体的共轭物组成，能够将dmg分子控制释放到受试者的组织中。还披露了将ProGel-药物共轭物用于治疗各种疾病或紊乱的方法以及制备它们的方法。
• C-7 modified flavonoids as novel tyrosyl-tRNA synthetase inhibitors
  作者：Zhu-Ping Xiao、Wei Wei、Qi Liu、Peng-Fei Wang、Xing Luo、Fang-Yuan Chen、Yang Cao、Hong-Xia Huang、Mi-Mi Liu、Hai-Liang Zhu

  DOI：10.1039/c6ra28061g

  日期：——

  Twenty C-7 modified flavonoids were designed and synthesized.

  二十种经过改良的C-7类黄酮类化合物被设计并合成。